Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Journey MedicalDERM -4.57%64 Cash-to-Debt is 1.00 as of Jun. 2026, which is 17% below its 10-year median of 1.21. GuruFocus rates DERM with a GF Score™ of 64/100 and a GF Value™ of $5.18 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Journey Medical ranks better than 51.07% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Journey Medical's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.00.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Journey Medicalcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Journey Medical's Cash-to-Debt or its related term are showing as below:
DERM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.75 Med: 1.21 Max: 188.92
Current: 1
During the past 7 years, Journey Medical's highest Cash to Debt Ratio was 188.92. The lowest was 0.75. And the median was 1.21.
DERM's Cash-to-Debt is ranked better than 51.07% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs DERM: 1.00
Journey Medical (NAS:DERM) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Journey Medical Cash-to-Debt Related Terms
Journey Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Journey Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Journey Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a Cash-to-Debt of 1.00 as of Jun. 2026. This is 17% below median its historical median of 1.21. Over the past decade, Journey Medical's Cash-to-Debt has ranged from 0.75 to 188.92. According to the industry distribution chart, Journey Medical ranks #481 out of 983 companies in the Drug Manufacturers industry, placing it in the top 48.9%.
Is Journey Medical's Cash-to-Debt too high?
Journey Medical's current Cash-to-Debt of 1.00 is 17% below median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 188.92. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Journey Medical's value of 1.00 is 4.2% above this industry median. Based on the distribution chart, Journey Medical ranks #481 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Journey Medical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Cash-to-Debt compare to SIGA and ORGO?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #481 out of 983 companies for Cash-to-Debt. This puts Journey Medical in the upper half of its industry. The industry median Cash-to-Debt is 0.96. Journey Medical's value of 1.00 is 4.2% above this benchmark. Historically, Journey Medical's own Cash-to-Debt has ranged from 0.75 to 188.92 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 0.96, Journey Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current Cash-to-Debt of 1.00 is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current Cash-to-Debt is 1.00, which is 17% below median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.18, compared to a current price of $6.99 — trading 34.9% above its estimated fair value. The current Cash-to-Debt is 1.00, which is 17% below median its 10-year median of 1.21 and 4.2% above the Drug Manufacturers industry median of 0.96. Journey Medical's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Journey Medical (DERM), the current Cash-to-Debt is 1.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.99 is trading 34.9% above its estimated GF Value™ of $5.18.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Cash-to-Debt: 1.00 (17% below median its 10-year median of 1.21)
GF Value™: $5.18 vs. price of $6.99 (34.9% above fair value)
Industry Position: 4.2% above the Drug Manufacturers median (#481 of 983)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
64GF Score
Get the complete analysis for DERM
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
